Cas 1056901-62-2 AT13148 AKT Inhibitors Oral Multi AGC Kinase Inhibitor
| Size | Price | Stock | Quantity |
|---|---|---|---|
| Get Quotation Now Add to Cart Bulk Inquiry | |||
AddThis Sharing Buttons
| Product name:AT13148 | Purity:98% min |
| CAS NO:1056901-62-2 | Solubility:DMSO50 mg/mL (159.35 mM) |
| Molecular Formula:C17H18Cl3N3O | Package:Package according to customer requirements |
| Molecular Weight:386.703 | Storage:Store at -20℃ |
AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors. AT13148 is currently being developed by Astex Pharmaceuticals. AT131148 was identified utilizing high-throughput X-ray crystallography and fragment-based lead discovery techniques. AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK and SGK substrate phosphorylation and induction of apoptosis in both a concentration and time-dependent manner in cancer cells with clinically relevant genetic defects both in vitro and in vivo.
Related Products
MK-2206 2HCl; Ipatasertib; Triciribine; PHT-427; Capivasertib; Perifosine; CCT128930; AT7867; ONC-201; Akti-1/2; SC66; Miltefosine; GSK690693;PF-4708671
[1].Yap TA, et al. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3912-23.
[2].Xi Y, et al. AT13148, a first-in-class m
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.